Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site by Usami, Yoshiko et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2007-04-13 
Potent rescue of human immunodeficiency virus type 1 late 
domain mutants by ALIX/AIP1 depends on its CHMP4 binding 
site 
Yoshiko Usami 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Repository Citation 
Usami Y, Popov S, Gottlinger HG. (2007). Potent rescue of human immunodeficiency virus type 1 late 
domain mutants by ALIX/AIP1 depends on its CHMP4 binding site. Open Access Articles. https://doi.org/
10.1128/JVI.00314-07. Retrieved from https://escholarship.umassmed.edu/oapubs/1315 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
JOURNAL OF VIROLOGY, June 2007, p. 6614–6622 Vol. 81, No. 12
0022-538X/07/$08.000 doi:10.1128/JVI.00314-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Potent Rescue of Human Immunodeficiency Virus Type 1 Late Domain
Mutants by ALIX/AIP1 Depends on Its CHMP4 Binding Site
Yoshiko Usami, Sergei Popov, and Heinrich G. Go¨ttlinger*
Program in Gene Function and Expression, Program in Molecular Medicine, University of
Massachusetts Medical School, Worcester, Massachusetts 01605
Received 12 February 2007/Accepted 29 March 2007
The release of human immunodeficiency virus type 1 (HIV-1) and of other retroviruses from certain cells
requires the presence of distinct regions in Gag that have been termed late assembly (L) domains. HIV-1
harbors a PTAP-type L domain in the p6 region of Gag that engages an endosomal budding machinery through
Tsg101. In addition, an auxiliary L domain near the C terminus of p6 binds to ALIX/AIP1, which functions in
the same endosomal sorting pathway as Tsg101. In the present study, we show that the profound release defect
of HIV-1 L domain mutants can be completely rescued by increasing the cellular expression levels of ALIX and
that this rescue depends on an intact ALIX binding site in p6. Furthermore, the ability of ALIX to rescue viral
budding in this system depended on two putative surface-exposed hydrophobic patches on its N-terminal Bro1
domain. One of these patches mediates the interaction between ALIX and the ESCRT-III component
CHMP4B, and mutations which disrupt the interaction also abolish the activity of ALIX in viral budding. The
ability of ALIX to rescue a PTAP mutant also depends on its C-terminal proline-rich domain (PRD), but not
on the binding sites for Tsg101, endophilin, CIN85, or for the newly identified binding partner, CMS, within
the PRD. Our data establish that ALIX can have a dramatic effect on HIV-1 release and suggest that the ability
to use ALIX may allow HIV-1 to replicate in cells that express only low levels of Tsg101.
The C-terminal p6 domain of the human immunodeficiency
virus type 1 (HIV-1) Gag polyprotein harbors a highly con-
served P(T/S)APP motif that is critical for virus replication in
most cell types (10). In adherent cells such as macrophages,
PTAPP mutants exhibit a defect at the level of virus release
from the cell surface, whereas in T-cell lines and primary
lymphocytes a defect in virion-virion detachment has been
noted (10, 14, 17). Functionally equivalent short sequence mo-
tifs that facilitate virus budding and release, collectively re-
ferred to as late assembly (L) domains, have also been identi-
fied in other retroviruses and in several other enveloped RNA
viruses. While most lentiviruses have L domains of the PTAP
type, the L domain of equine infectious anemia virus (EIAV)
maps to a conserved YPxL sequence, and other retroviruses
harbor a conserved PPxY motif in Gag that is required for
efficient budding (12). Remarkably, L domains do not depend
on a particular location within Gag to function and can even be
moved between unrelated viruses (37), an observation that
suggested that L domains may act as docking sites for cellular
factors.
Indeed, it is now clear that the PTAP-type L domain in
HIV-1 p6 recruits the host protein Tsg101, which is essential
for HIV-1 budding from adherent cells (9, 13, 31, 44). Tsg101
is a component of the ESCRT-I complex, which mediates the
sorting of cargo into vesicles that bud form the limiting mem-
brane into the lumen of multivesicular bodies (MVBs) (2, 15,
22). Virus budding at the cell membrane and vesicle formation
at the MVB are topologically related, and ESCRT-I could thus
have similar roles in both budding events. In yeast, the absence
of any of three of the four components of ESCRT-I leads to
the accumulation of an aberrant endosome-derived structure
called the class E compartment (21). Altogether, at least 17
distinct class E vacuolar protein sorting (Vps) proteins appear
to be required for MVB biogenesis and are conserved from
yeast to humans (2). Apart from ESCRT-I, class E Vps pro-
teins are the constituents of two additional heteromeric endo-
somal sorting complexes called ESCRT-II and ESCRT-III.
ESCRT-II is activated by ESCRT-I and in turn stimulates the
assembly of ESCRT-III on endosomal membranes (3, 4). In
humans, ESCRT-III is formed by the charged MVB proteins
(CHMPs), which belong to a large family of distantly related
coiled-coil proteins (16, 45). At least some of the CHMPs
interact with the ATPase Vps4 (30, 45), a class E Vps protein
that disassembles the ESCRT complexes for further rounds of
sorting (3, 5). Retroviral budding in general exhibits a remark-
able sensitivity to mutant versions of Vps4 or of the CHMPs
(13, 30, 43, 45, 51), indicating that all types of L domains
ultimately engage the MVB sorting machinery.
In addition to the Tsg101 binding site, HIV-1 p6 contains a
region that has an auxiliary role in virus release and binds to
ALIX/AIP1 (43). ALIX also binds avidly to the YPxL-type L
domain of EIAV and is required for EIAV budding (30, 43,
45). Intriguingly, ALIX interacts with Tsg101 through a PSAP
motif in its C-terminal proline-rich domain (PRD) (43, 45),
which also binds to endophilin, CIN85, and ALG-2 (35). ALIX
has been linked to MVB biogenesis on the basis of its affinity
for the unconventional phospholipid lysobisphosphatidic acid,
which is abundant in the internal membranes of MVBs (32). A
role in the MVB pathway is also suggested by the observation
that ALIX binds to CHMP4 proteins via its N-terminal Bro1
domain (19, 30, 43, 45), which is further reported to interact
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with a Rab GTPase-activating protein (18). Bro1, one of the
two yeast homologs of ALIX, functions in the MVB pathway
and associates with endosomes in a manner that depends spe-
cifically on SNF7, the single yeast homolog of the human
CHMP4 proteins (36). The other yeast homolog of ALIX is an
essential component of a signal transduction pathway that also
depends on SNF7 and on Vps23, the Saccharomyces cerevisiae
ortholog of Tsg101 (27, 48, 49).
HIV-1 mutants that lack the Tsg101 binding site in p6 ex-
hibit a severe release defect in adherent cells, which implies
that the ALIX binding site alone is not sufficient for efficient
virus budding. However, we now report that Tsg101 binding
site mutants can be efficiently rescued by increasing the cellular
expression levels of ALIX. We also show that the binding site
for CHMP4B on the Bro1 domain of ALIX is required for this
activity, as is a second putative interaction surface on the Bro1
domain. Interestingly, while the binding sites for Tsg101, en-
dophilin, CIN85, and CMS in the PRD are all dispensable, the
very C terminus of the PRD is essential and may connect ALIX
to an as-yet-unidentified cofactor that is required for its func-
tion in virus budding.
MATERIALS AND METHODS
Proviral constructs. HXBH10, the parental proviral plasmid used in this study,
is a vpu-positive version of the infectious HXB2 proviral clone of HIV-1. The
PTAPP mutant is a variant of HXBH10 with an in-frame deletion of codons 7
through 11 of p6 (25). The PTAP/LIRL mutant of HXBH10 has a 4-amino-acid
substitution of the PTAP L domain in p6 that does not change the coding
sequence of the overlapping pol reading frame (17). Similarly, the T8I mutation
targets the PTAP motif, and the previously described Y36s mutation (14) intro-
duces a premature termination codon in place of Tyr-36 of p6 without altering
the pol frame.
Expression vectors. The expression vectors for HA-ALIX, HA-ALIXPRD,
CHMP31–150FLAG, and FLAG-CMS have been described previously (24, 43,
51). An EagI-SmaI fragment encoding ALIX residues 1 to 847 with an N-
terminal hemagglutinin (HA) tag was excised from the HA-ALIX vector and
subcloned between the NotI and EcoRI sites (filled in with Klenow enzyme) of
pBJ5. This yielded an expression vector for HA-ALIX1–847 followed by two
unrelated amino acids. An EcoRV site near the 3 end of the ALIX coding
sequence was used to insert premature termination codons directly after ALIX
codons 853, 858, and 863 using a PCR-based cloning strategy. ALIX point
mutants were made using the QuikChange mutagenesis strategy (Stratagene).
The coding sequence for CIN85 with a C-terminal HA tag was amplified from
BC015806 (Open Biosystems) and that of endophilin 2 with an N-terminal HA
tag from BC001270. The primers incorporated restriction sites that were used to
clone the PCR fragments between the XhoI and EcoRI sites of pBJ5. For the
expression of glutathione S-transferase (GST)–ALIX PRD fusion proteins, PCR
fragments encompassing ALIX residues 714 through 868 or mutant versions of
the same region were inserted in frame between the EcoRI and XhoI sites of
pCAGGS/GST (30).
Analysis of viral particle production. 293T cells (1.2  106) were seeded into
T25 flasks and transfected 24 h later using a calcium phosphate precipitation
technique. The cultures were transfected with 1 g of HIV-1 proviral DNA
together with expression vectors for wild-type (WT) or mutant HA-ALIX (be-
tween 1 and 3 g) and, where indicated, for CHMP31–150FLAG (0.5 g) or the
appropriate empty vectors. The total amount of transfected DNA was brought to
8 g with carrier DNA (pTZ18U). Twenty-four hours posttransfection, the cells
were lysed in radioimmunoprecipitation assay buffer (140 mM NaCl, 8 mM
Na2HPO4, 2 mM NaH2PO4, 1% Nonidet P-40 [NP-40], 0.5% sodium deoxy-
cholate, 0.05% sodium dodecyl sulfate [SDS]), and the culture supernatants were
clarified by low-speed centrifugation and passaged through 0.45-m filters. Viri-
ons released into the medium were then pelleted through 20% sucrose cushions
and analyzed as described elsewhere (1) by SDS-polyacrylamide gel electro-
phoresis (PAGE) and Western blotting with a rabbit anti-HIV CA serum (Ad-
vanced Biotechnologies). Proteins in the cell lysates were detected by Western
blotting with rabbit anti-HIV CA serum or with anti-HA antibody HA.11 (Co-
vance).
Coimmunoprecipitations. 293T cells (3.5  106) were seeded into T80 flasks
and cotransfected with expression vectors for FLAG-tagged WT or mutant
ALIX and HA-tagged CHMP4B (8 g each). Twenty-four hours posttransfec-
tion, the cells were lysed in NP-40 buffer (0.5% NP-40, 20 mM Tris HCl [pH 7.4],
150 mM NaCl, and protease inhibitor cocktail [Complete; Roche Molecular
Biochemicals]). The lysates were centrifuged at 16,000  g and immunoprecipi-
tated for 2.5 h at 4°C with anti-FLAG antibody M2 (Sigma). Immunoprecipitates
and the cell lysates were analyzed by immunoblotting with anti-HA or anti-
FLAG antibody as indicated.
GST pull-down assay. 293T cells seeded into T80 flasks were cotransfected
with expression vectors for GST- and either HA- or FLAG-tagged proteins (5 g
each) together with 8 g carrier DNA. Twenty-four hours later the cells were
lysed in 0.5% NP-40 buffer, and clarified lysates were incubated with glutathione-
Sepharose beads (GE Healthcare) for 2.5 h at 4°C. After extensive washing in
NP-40 buffer, bound proteins were eluted by boiling in SDS-PAGE sample buffer
and resolved by SDS-PAGE. Epitope-tagged proteins were detected by Western
blotting with anti-HA or anti-FLAG M2 antibody, and GST fusion proteins were
visualized with colloidal Coomassie brilliant blue G-250.
Protein identification. A 70-kDa protein pulled down by WT GST-PRD ex-
pressed in 293T cells, but not by the PR744AG mutant, was excised from a
Coomassie-stained gel and subjected to in-gel tryptic digestion. Extracted pep-
tides were analyzed on a Shimadzu Biotech Axima TOF2 (Shimadzu Instru-
ments) matrix-assisted laser desorption ionization–time-of-flight mass spectrom-
eter. Peptide mass fingerprinting yielded 31 peptides that matched CMS/
CD2AP, and collisionally induced dissociation analysis of the six most abundant
peptides verified the peptide mass fingerprint identification.
RESULTS
Exogenous ALIX rescues particle production by Tsg101
binding site mutants. While examining the ability of HIV-1 p6
mutants to replicate in T-cell lines, we noticed that Jurkat cells
are partially permissive for viruses that have only the Tsg101 or
only the ALIX binding site mutated but are much less permis-
sive for a virus that harbors both mutations simultaneously
(data not shown). This observation prompted us to explore the
possibility that ALIX, if expressed at sufficiently high levels,
can complement viruses defective for Tsg101 binding. To ex-
amine this possibility, we first used the previously described
PTAPP mutant of the infectious HXBH10 molecular clone,
which lacks the entire Tsg101 binding site and exhibits a severe
defect in particle release in adherent cells (1). The PTAPP
provirus was transfected into 293T cells along with an expres-
sion vector for HA-ALIX or the empty vector. Remarkably,
the coexpression of HA-ALIX led to a profound increase in
viral particle production by the PTAPP mutant (Fig. 1A, left
panel). Furthermore, exogenous HA-ALIX at least partially
corrected the Gag processing defect of the PTAPP mutant,
which is characterized by the accumulation of the cleavage
intermediates CA-p2 and p41 and is considered a hallmark of
late assembly defects. Exogenous HA-ALIX also profoundly
improved particle production by a mutant that had the Tsg101
binding site replaced without changing the overlapping pol
reading frame (Fig. 1A, right panel). As previously reported
(17), this mutant released essentially no mature CA when
cotransfected with the vector control.
A side-by-side comparison of the PTAPP mutant and the
WT virus confirmed the dramatic particle release defect of the
mutant (Fig. 1B, lanes 1 and 5). Nevertheless, HA-ALIX res-
cued particle production by the PTAPP mutant to WT levels
(lanes 4 and 5). In contrast, HA-ALIX had no effect on the WT
virus (lane 8). We also examined whether HA-ALIX sup-
presses the effect of CHMP31–150FLAG, a truncated version of
the ESCRT-III component CHMP3 that blocks HIV-1 bud-
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ding (Fig. 1B, lane 6), as previously reported (51). However,
HA-ALIX rescued neither the WT virus nor the PTAPP
mutant in the presence of CHMP31–150FLAG (lanes 3 and 7).
We conclude that the dominant-negative effect of CHMP31–150
FLAG does not depend on the Tsg101 binding site in p6.
We previously showed that an LYP and an LxxLF motif in a
C-terminal region of p6 are required for the interaction with
ALIX (43). To determine whether this region is also required
for the rescue of a Tsg101 binding site mutant by HA-ALIX,
we used a provirus that harbors both a point mutation in the
PTAP L domain (T8I) and a premature termination codon
(Y36s) near the C terminus of p6 that removes the LYP and
LxxLF motifs. While the T8I mutant exhibited a defect in virus
release as reported previously (17), at least in 293T cells par-
ticle production was somewhat easier to detect than with the
PTAPP mutant (Fig. 2), perhaps because the T8I mutation
disrupts only part of the Tsg101 binding site (13). In the con-
text of the T8I mutant, the Y36s truncation did not further
reduce particle production but caused a moderate accumula-
tion of the CA-p2 cleavage intermediate in virions. Interest-
ingly, while the coexpression of HA-ALIX clearly increased
particle production by the T8I mutant and improved the pro-
cessing of cell-associated Gag, both of these effects were abol-
ished by the Y36s truncation (Fig. 2) and by a 2-amino-acid
substitution in the LxxLF motif (LF45PS) that prevents the
interaction with ALIX (43) (data not shown). We conclude
that the rescue of Tsg101 binding site mutants by HA-ALIX
requires the presence of an intact ALIX binding site in p6.
CHMP4B binding site mutants of ALIX fail to rescue HIV-1
budding. We and others have shown that ALIX interacts with
all three human CHMP4 isoforms (19, 30, 43, 45). However,
the interaction with CHMP4B is particularly robust (19).
Vps32/SNF7, the single yeast ortholog of the human CHMP4
proteins, binds to the N-terminal Bro1 domain of the ALIX
homolog Bro1 (23). The crystal structure of the Bro1 domain
of the yeast protein reveals a boomerang-shaped folded core of
367 residues with two exposed hydrophobic patches (23). In-
terestingly, certain point mutations in patch 1 disrupted the
interaction with SNF7, indicating that patch 1 constitutes at
least part of the binding site (23).
ALIX shares an N-terminal Bro1 domain with its yeast ho-
molog, and at least some of the residues that make up hydro-
phobic patch 1 on the Bro1 domain are conserved among the
yeast and human proteins. This is particularly evident for Phe-
199 and Leu-216 of ALIX, which correspond to patch 1 resi-
dues Phe-189 and Leu-209 of Bro1. Additionally, Ile-148, Ala-
FIG. 1. Rescue of Tsg101 binding site mutants by ALIX. (A) Ex-
ogenous ALIX profoundly increases the release of virions by HIV-1
mutants that have the PTAP L domain either deleted or replaced
without changing the overlapping pol frame. 293T cells were trans-
fected with mutant HIV-1 proviral DNA (1 g) and either empty pBJ5
or a version expressing HA-ALIX (3 g). Virion production and Gag
expression levels were compared by Western blotting with anti-CA
serum. (B) ALIX increases virion production by PTAPP HIV-1 to
WT levels, and its effect is blocked by dominant-negative CHMP3.
293T cells were transfected with HIV-1 proviral DNA (1 g) together
with expression vectors for HA-ALIX (2 g), and/or CHMP31–150FLAG
(0.5 g), as indicated. Virion production and Gag expression were
compared as above, and the expression of tagged ALIX was deter-
mined by Western blotting with anti-HA.
FIG. 2. The rescue of a Tsg101 binding site mutant by ALIX de-
pends on the ALIX binding site in p6. 293T cells were transfected with
the indicated HIV-1 p6 mutants (1 g) and either empty pBJ5 or a
version expressing HA-ALIX (3 g). Virion production and Gag ex-
pression levels were compared by Western blotting with anti-CA se-
rum. The T8I substitution targets the Tsg101 binding site, and the Y36s
truncation removes the ALIX binding site.
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149, and Leu-213 of ALIX appear to correspond to patch 1
residues Ile-144, Ala-145, and Leu-206 of its yeast homolog.
To examine the importance of these putative patch 1 resi-
dues for the activity of ALIX in virus budding, we changed
each of these residues to Asp. This substitution was chosen
because of previous work showing that the replacement of
Bro1 residues Ile-144 and Leu-336 by Asp disrupts the inter-
action with SNF7 (23). All mutations were introduced into
N-terminally HA-tagged ALIX to allow a comparison of the
expression levels of the WT and mutant proteins. As shown in
Fig. 3A, one mutant (IA148SD) was poorly expressed and
therefore not analyzed further. The I148D and I213D mutants
were expressed at WT levels and retained the ability to rescue
particle production by the p6 PTAPP mutant (Fig. 3A, lanes
3 and 6), albeit at a reduced level compared to WT ALIX (lane
2). In contrast, the F199D and L216D mutants showed no ac-
tivity in this assay (lanes 5 and 7). Whereas the F199D mutation
did not affect the expression of ALIX, the L216D mutant was
expressed at a slightly lower level than the WT protein. There-
fore, we performed an additional experiment in which the
amount of vector encoding the L216D mutant was doubled.
Although this led to expression levels for the mutant protein
that approached those obtained for WT ALIX in the same
experiment, the L216D mutant again proved unable to rescue
particle production by the PTAPP HIV-1 provirus (Fig. 3B).
To determine the effects of the patch 1 mutations on the
interaction between ALIX and CHMP4B in human cells, we
used a previously described coprecipitation assay (43). The
I148D, F199D, I213D, and L216D mutations were individually
introduced into FLAG-tagged ALIX, and the mutants were
coexpressed in 293T cells together with HA-tagged CHMP4B.
The cells were then lysed in 0.5% NP-40 buffer, and proteins
precipitated from the lysates with anti-FLAG antibody were
analyzed by Western blotting. As expected, CHMP4B-HA co-
precipitated specifically with WT ALIX-FLAG (Fig. 4, lanes 1
and 2). Interestingly, whereas the I148D and I213D mutations
had little effect on the coprecipitation of CHMP4B-HA (lanes
3 and 5), the F199D and L216D mutations abolished the inter-
action between ALIX and CHMP4B (lanes 4 and 6). Since the
F199D and L216D mutations also abolished the rescue of
PTAPP HIV-1 by ALIX, these data indicate that the ability
to interact with CHMP4B is required for the function of ALIX
in viral budding.
Surface patch 2 is crucial for the function of ALIX in HIV-1
budding. In addition to the binding site for SNF7, the crystal
FIG. 3. Effects of mutations targeting surface patch 1 of the ALIX Bro1 domain on the ability of ALIX to rescue virion release by PTAPP
HIV-1. (A) 293T cells were transfected with the PTAPP mutant (1 g) and vectors expressing WT HA-ALIX or the indicated mutants, or empty
vector (2 g). Virion production and the expression levels of Gag and HA-ALIX were monitored by Western blotting. (B) Comparison of the
abilities of WT and L216D ALIX to rescue virion release when expressed at similar levels. 293T cells were transfected with the PTAPP mutant
(1 g) and vectors expressing WT HA-ALIX (2 g), L216D HA-ALIX (4 g), or empty vector (2 g).
FIG. 4. Effects of mutations targeting surface patch 1 of the ALIX
Bro1 domain on the interaction with CHMP4B. 293T cells were co-
transfected with vectors expressing WT ALIX-FLAG or the indicated
mutants together with CHMP4B-HA. The cell lysates and proteins
immunoprecipitated (IP) with anti-FLAG antibody were analyzed by
Western blotting (WB) as indicated.
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structure of the Bro1 domain revealed a second hydrophobic
patch at one tip of the boomerang (23). Because of the striking
exposure of several hydrophobic residues in this patch to sol-
vent, it has been proposed that patch 2 is an interaction site for
an unknown ligand (23). Interestingly, the three hydrophobic
side chains in the patch that are hyperexposed (Phe-318, Ile-
319, and Tyr-320) are conserved between yeast Bro1 and hu-
man ALIX, where the equivalent residues are Phe-317, Ile-318,
and Tyr-319. Furthermore, these three residues are located
within a highly conserved sequence context that also includes
several charged or polar residues and which represents the
most conserved region of ALIX.
To examine the role of this conserved region in the virus
release function of ALIX, we individually replaced the three
consecutive hydrophobic residues, Phe-317, Ile-318, and Tyr-
319, with alanine in the context of HA-tagged ALIX. In addi-
tion, one of the polar residues in the conserved region (Asp-
316) was changed to alanine. In the crystal structure of yeast
Bro1, the side chain of the corresponding residue (Asp-317) is
directly adjacent to the hydrophobic side chains that form
surface patch 2 (23). As shown in Fig. 5, neither of these
mutations affected the expression levels of HA-ALIX in 293T
cells. However, only the D316A mutant remained as active as
WT ALIX in rescuing the budding defect of PTAPP HIV-1
(Fig. 5, lanes 2 and 3). While one of the hydrophobic patch
mutants (F317A) also retained some activity, the other two
(I318A and Y319A) were poorly active in this assay, particularly
the I318A mutant (Fig. 5, lanes 4 to 6). We thus conclude that
hydrophobic patch 2 is critical for the role of ALIX in virus
release.
Essential role of the very C terminus of ALIX. In addition to
the N-terminal Bro1 domain, all ALIX homologs share a C-
terminal PRD which, in the case of human ALIX, spans 152
amino acids. The PRD is thought to be largely unstructured
and to contain multiple docking sites for other cellular pro-
teins. Interaction partners that have been identified include
Tsg101 (43, 45), CIN85 (8), endophilin (7), and ALG2 (33).
To determine whether the PRD is required for the rescue of
PTAPP HIV-1 by ALIX, we first used a previously described
FIG. 5. Effects of mutations targeting surface patch 2 of the ALIX
Bro1 domain on the ability of ALIX to rescue virion release by
PTAPP HIV-1. 293T cells were transfected with the PTAPP mutant
(1 g) and vectors expressing WT HA-ALIX or the indicated mutants,
or empty vector (1 g). Virion production and the expression levels of
Gag and HA-ALIX were monitored by Western blotting.
FIG. 6. Effects of ALIX PRD truncations on the rescue of PTAPP
HIV-1. (A) The PRD is essential for the rescue of virus release by
ALIX. 293T cells were transfected with HIV-1 proviral DNAs (1 g)
and either empty pBJ5 or versions expressing HA-ALIX or HA-
ALIXPRD (3 g). Virion production and the expression levels of Gag
and HA-ALIX were monitored by Western blotting. (B) The very C
terminus of the PRD is required for the activity of ALIX in virus
release. 293T cells were transfected with the PTAPP mutant (1 g)
and vectors expressing WT HA-ALIX or the indicated truncation
mutants, or empty vector (1 g).
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C-terminal truncation mutant called HA-ALIXPRD, which
retains the first 702 residues of ALIX (43). As shown in Fig.
6A, the coexpression of ALIXPRD did not at all improve
particle production by the PTAPP mutant (lane 4). In
marked contrast, WT ALIX expressed at similar levels again
rescued particle production to the level obtained with WT
HIV-1 (lane 3). Since ALIXPRD lacks 14 residues upstream of
the PRD, we next tested a series of truncation mutants that
lacked only PRD residues. The results of these experiments
showed that ALIX1–847 as well as mutants with more extensive
deletions into the PRD all had completely lost the ability to
rescue the particle release defect of PTAPP HIV-1 (Fig. 6B
and data not shown). ALIX1–847 retains the binding site for
ALG-2, because it has been shown that ALIX796–847 is suffi-
cient for full binding activity (41). Furthermore, ALIX1–847
retains the reported binding sites for Tsg101, CIN85, and en-
dophilin (7, 26, 40, 45). We thus infer that the presence of
binding sites for all of the known PRD interaction partners is
not sufficient for the function of the PRD in HIV-1 budding.
The inactive ALIX1–847 mutant lacks the 21 C-terminal res-
idues of ALIX. To map the essential C-terminal region in more
detail, we generated three additional truncation mutants that
lacked only the 15 (ALIX1–853), 10 (ALIX1–858), or 5 (ALIX1–863)
C-terminal residues of the PRD. When tested for their ability
to rescue virion release by PTAPP HIV-1, ALIX1–853 and
ALIX1–858 showed no activity at all in repeated experiments
(Fig. 6B). ALIX1–863, which lacks only the sequence YYPQQ
at the C terminus of ALIX, increased virus particle production
only slightly (Fig. 6B). These data indicate that the very C
terminus of the PRD is essential for the ability of ALIX to
promote virus budding.
Role of specific protein interaction sites in the ALIX PRD.
We specifically targeted the interaction sites for Tsg101,
CIN85, and endophilin to determine whether these are re-
quired to rescue HIV-1 budding in our assay. The PS717AI
mutation was designed to disrupt the 717PSAP720 motif at the
very beginning of the PRD, which constitutes the Tsg101 bind-
ing site of ALIX (45). The PR744AG mutation targets 740PTP
APR745, which conforms to the atypical PxxxPR polyproline-
arginine motif recognized by the SH3 domains of CIN85 (26).
Lastly, the RPP757GAA mutation disrupts the sequence 754PP
ARPP759, which matches the consensus binding site for en-
dophilin (28). As shown in Fig. 7, none of these mutations
compromised the ability of HA-ALIX to rescue virus particle
production by PTAPP HIV-1.
To confirm that the mutations in the PRD affected the
interaction with CIN85 or endophilin, we expressed GST-PRD
fusion proteins in human 293T cells together with epitope-
tagged binding partners and performed GST pull-down assays.
As can been seen in Fig. 8A, the PR744AG mutation abolished
the interaction with CIN85, as expected. Furthermore, we ob-
served that the RPP757GAA mutation drastically impaired the
interaction with endophilin 2 (Fig. 8B), the ubiquitously ex-
pressed member of the endophilin family (38).
During the course of these experiments, we noticed that the
WT GST-PRD fusion protein specifically coprecipitated a pro-
tein of about 70 kDa, and microsequencing unequivocally
identified this protein as CMS/CD2AP (data not shown; see
Materials and Methods). CMS belongs to the same family of
endocytic adaptor proteins as CIN85, and its SH3 domains
recognize the same proline-arginine motif as those of CIN85
(34). However, it has been proposed that, in addition to 740P
TPAPR745, ALIX may contain a second binding site for CMS
that overlaps with the endophilin binding site (752PQPPARP758).
As shown in Fig. 8C, the interaction between the ALIX PRD
and CMS was abolished by the PR744AG mutation but unaf-
fected by the RPP757GAA mutation, indicating that the PRD
contains only one binding site for CMS. Taken together, our
results imply that the interactions with Tsg101, CIN85, CMS,
and endophilin are all dispensable for the rescue of HIV-1
budding by ALIX.
DISCUSSION
In this study, we have shown that exogenous ALIX can fully
correct the profound budding defect of HIV-1 mutants that
lack the PTAP-type primary L domain near the N terminus of
p6. Exogenous ALIX also alleviated the characteristic Gag
processing defect of PTAP mutants, but this effect was less
robust and more variable between experiments than the effect
on virus release. While the reason for this is not known, it may
be that impaired processing of mature CA in particular is a
more sensitive indicator of an L domain defect than impaired
virus release and, thus, more difficult to correct.
The rescue of virus budding by ALIX was fully dependent on
the integrity of the ALIX binding site near the C terminus of
p6, confirming the functional relevance of the interaction be-
tween ALIX and p6. While in established cell lines the ALIX
binding site is less critical for virus release and/or infectivity
than the Tsg101 binding site, the contribution of the ALIX
FIG. 7. The binding sites for Tsg101, CIN85, CMS/CD2AP, and
endophilin are dispensable for the ability of ALIX to rescue virus
release by PTAPP HIV-1. 293T cells were transfected with the
PTAPP mutant (1 g) and vectors expressing WT HA-ALIX or the
indicated PRD mutants (1 g). Virion production and the expression
levels of Gag and HA-ALIX were monitored by Western blotting.
PS717AI targets the binding site for Tsg101, PR744AG targets the
binding site for CIN85 and CMS/CD2AP, and RPP757GAA targets the
binding site for endophilin.
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binding site would be expected to be more evident in cells that
express relatively low levels of Tsg101. Indeed, HIV-1 may
have evolved the ability to use both Tsg101 and ALIX to cope
with situations in which the expression level of one of these
cellular factors alone is insufficient to support efficient virus
replication.
Several lines of evidence suggest that HIV-1 budding de-
pends on an intact class E Vps vesicle formation pathway. For
instance, HIV-1 budding requires Tsg101 and is strongly in-
hibited by a defective version of Vps4, the ATPase which
recycles class E Vps proteins (13). Furthermore, HIV-1 bud-
ding is potently blocked by various dominant-negative versions
of the CHMPs, the components of ESCRT-III (30, 45, 51).
Nevertheless, it has recently become clear that HIV-1 budding
is unaffected by the depletion of a subunit of ESCRT-II (29),
which at least in yeast is an essential component of the MVB
biogenesis pathway (4). Perhaps even more surprisingly, given
the strong inhibitory effect of mutant CHMPs on retrovirus
budding, HIV-1 release was also unaffected by the efficient
depletion of CHMP5 or CHMP6 (29, 47). The yeast ortholog
of CHMP6 is myristylated and, together with the yeast or-
tholog of CHMP4, forms a subcomplex that is required for the
membrane association of ESCRT-III (3). Human CHMP6 is
also myristylated and interacts directly with CHMP4B (50),
suggesting that it has a similar function in ESCRT-III assembly
as its yeast ortholog. The observation that CHMP6 is appar-
ently dispensable for HIV-1 budding thus argues against a
requirement for the full ESCRT-III complex.
However, our results now provide evidence for a role of at
least one of the components of ESCRT-III in HIV-1 release.
ALIX interacts with the ESCRT-III component CHMP4B (30,
43, 45), and this interaction is mediated by the N-terminal Bro1
domain (20). Based on the structure of the Bro1 domain of
yeast Bro1, we have mutated the putative binding site and
found that point mutations that abolish the interaction with
CHMP4B also abolish the function of ALIX in HIV-1 bud-
ding. In yeast, the endosomal association of Bro1 specifically
depends on the CHMP4 homolog SNF7 (36), and there is also
evidence that the recruitment of ALIX to endosomes is medi-
ated by CHMP4 proteins (20). Thus, one possible explanation
for our findings is that ALIX must be targeted to endosomes in
order to function in viral budding. However, a recent study
suggests that ALIX is also found in discrete endosome-like
domains of the plasma membrane that are competent for out-
ward vesicle budding and that ALIX and HIV-1 Gag colocalize
in these domains (6). Another possibility is that the association
of CHMP4B allows ALIX to recruit yet another factor that is
required for its function. This scenario is not unprecedented,
because an ALIX homolog that acts in the fungal pH response
pathway recruits a downstream effector through SNF7 (48).
The structure of the yeast Bro1 domain points to the exis-
tence of a second hydrophobic interaction surface (23), and the
exceptionally high degree of conservation of the residues that
contribute to this surface among ALIX homologs implies func-
tional importance. Our results establish that the three hydro-
phobic residues at the core of this surface are indeed important
for the ability of ALIX to promote HIV-1 budding. It has been
reported that one of these residues (Tyr-319) is phosphory-
lated by the Src tyrosine kinase, which antagonizes the activity
of ALIX as a regulator of receptor endocytosis (39). However,
we consider it unlikely that a requirement for Tyr-319 phos-
phorylation explains the effects we observed. First, Ile-318 is at
least as important as Tyr-319 for the activity of ALIX in HIV-1
budding but is not part of the consensus sequence for a ty-
rosine kinase phosphorylation site. Second, one of the residues
that does match the consensus (Asp-316) was dispensable for
the activity of ALIX in our assay.
ALIX connects to interaction partners not only through its
Bro1 domain but also through its C-terminal PRD. Although
dispensable for the interaction between ALIX and HIV-1 p6
(43), the PRD nevertheless proved to be essential for the
FIG. 8. Effects of mutations in the ALIX PRD on the interactions
with CIN85, endophilin, and CMS/CD2AP in human cells. (A) The
PR744AG mutation abolishes the interaction with CIN85-HA. GST-
PRD fusion proteins were expressed in 293T cells together with
CIN85-HA, and proteins precipitated from the cell lysates by glutathi-
one-Sepharose beads were analyzed by Western blotting with anti-HA
or by Coomassie staining to detect the GST-PRD fusion proteins.
(B) GST pull-down assays performed as for panel A, showing that the
RPP757GAA mutation severely impairs the interaction with endo-
philin. (C) GST pull-down assays performed as for panel A, showing
that the PR744AG mutation also abolishes the interaction with FLAG-
CMS, whereas the RPP757GAA mutation does not affect this inter-
action.
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rescue of a Tsg101 binding site mutant in 293T cells. This
observation contrasts with our previous finding that the over-
expression of ALIXPRD in HeLa cells significantly increased
virus-like particle production by minimal HIV-1 Gag con-
structs, even though these lacked the ALIX binding site in p6
(43). However, no rescue was observed if p6 was deleted en-
tirely (43). Thus, consistent with the present study, ALIXPRD
was unable to rescue a mutant that lacked the Tsg101 bind-
ing site.
Endophilin, one of the known interaction partners of the
ALIX PRD, is constitutively associated with the adaptor pro-
tein CIN85, which independently binds to the ALIX PRD (42).
CIN85 also associates with the ubiquitin ligase Cbl and plays a
role in the delivery of activated tyrosine kinase receptors to
late endosomes (42). In the present study, we additionally
identified CMS, an endocytic adaptor protein related to
CIN85, as a binding partner for the PRD of ALIX. Intrigu-
ingly, endophilin has a BAR domain through which it can
generate membrane curvature (11) and is thus a plausible
candidate for a factor involved in retrovirus release. Indeed, it
has been reported that endophilin 2 specifically interacts with
the Gag protein of Moloney murine leukemia virus (46). Fur-
thermore, the overexpression of endophilin selectively inhib-
ited virion production by Moloney murine leukemia virus, and
it was therefore suggested that endophilin is hijacked by ret-
roviruses to promote virion production (46). Nevertheless, our
results indicate that the interactions of ALIX with endophilin,
CIN85, or CMS are all dispensable for the activity of ALIX in
HIV-1 budding, as is the interaction with Tsg101. In contrast,
the very C terminus of the PRD is essential for the activity,
and the identification of a binding partner for this region
may shed light on the mechanism by which ALIX promotes
virus budding.
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